MEREO BIOPHARMA GROUP

• 72110 - Research and experimental development on biotechnology

Mereo BioPharma (Mereo) was founded in March 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017. In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products. Thanks to this merger, we have been able to strengthen the balance sheet, broaden our shareholder base and further diversity our product portfolio, adding two additional clinical stage oncology programs to our pipeline... London, September 7, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate..

Also known as: Mereo BioPharma, MEREO BIOPHARMA GROUP PLC

Registration numbers: 09481161 (CH)

Primary location: London United Kingdom